The Cannavist USA Issue 1 | Page 35

“In the traditional biopharma space, I could never get involved with politics. That’s a no no. You know how it works, they pay for lobbyists and you have to stay out of it – especially in clinical research. With medical cannabis and CBD, I can get involved with politics. I advocated on behalf of patients before city council, for decriminalization proceedings, working on a federal level with the American Society of Cannabis Medicine, so I’m down The Hill quite often. “Now I’m lobbying, I’m meeting with politicians, I’m speaking out on behalf of patients in f ront of the public and testifying on their behalf.” She makes money moves What do words like research, biopharma and advocacy all have in common? Money. As CEO, Christina knows all too well that there are people out there who tug on the strings of compassion. She says, “People call and ask if we will donate our services. But we can’t. We have to work, we have to make a living. We don’t charge the same price points in medical cannabis and CBD research that they do on the traditional side out of respect.” The CBD and medical cannabis industries are on the cusp of a boom, but funding to back research, or a lack thereof, is still a problem. Christina says, “There isn’t enough funding. People need to understand it’s going to take ‘X’ amount of money to get you to that f inish line. You have to make sure you raise enough or continue to sustain a raise after your f irst couple of studies.” While securing funding is an uphill climb for any campaign, this total girl boss doesn’t believe in the green rush everyone else is talking about. “Everybody is in a rush around here. They’re putting it [CBD] in everything… coffee, tea, cookies, ice cream, water, juice. It’s too much! We’re overloading now, you’re flooding your endocannabinoid system with all of these different terpene prof iles, you have to stick with what works for you. Bath bombs are great but this not a get rich quick scheme!” Something which has cost an eye- watering amount of money is Christina’s precious CannaBot. “We designed the little bot. I’m really proud of this. It’s an artif icial intelligence platform that patients can use to be educated at the public domain and the subscriber can issue them authorization for access through the private domain.” The two-tiered system offers answers to f requently asked questions which those curious about CBD and medical cannabis might have, while CannaBot can also provide more bespoke information and services via a private gateway and the cherry on the cake? “It’s all voice activated through Alexa and Google.” At this point Christina’s off ice Alexa interrupted our interview. That’s AI for you! As the multi-talented and skilled entrepreneur approaches the f ifth anniversary of her father’s passing, she hopes to host a major event in his memory through Aff inity Patient Advocacy, her non-prof it, later this year. “This is all stuff I couldn’t have done in the traditional side. It’s all stuff that my dad wanted me to be involved in since I was a kid, since I was in High School. It’s nice to have that opportunity to bring it back full circle.” “ “In the traditional biopharma space, I could never get involved with politics. That’s a no no. Now I’m lobbying, I’m meeting with politicians, I’m speaking out on behalf of patients in front of the public and testifying on their behalf.” “ Fast forward to 2019 and Christina is CEO and founder of Affi nity Bio Partners; CEO and Board President of Affi nity Patient Advocacy; CEO and co-founder of AI Health Outcomes of which the CannaBot is an artifi cial intelligence brainchild. In her spare time, Christina co-hosts YouTube show ‘Coming Out With Cannabis’ and is a Board Member of the American Society of Cannabis Medicine (ASCM). Her role is still research-focused, but she can voice her educated opinion on matters now as a woman in business, and also as an advocate, something a career in Big Pharma could never afford her. 35